Lavamisole Withdrawal: EMA & Drug List – Risk of Brain Damage
European Medicines Agency Pulls Levamisole from Market Amidst Brain Damage Concerns A critical safety review has prompted the European Medicines Agency (EMA) to withdraw authorization for all medicines containing levamisole, a drug previously used to treat certain parasitic worm infections and as an adjunct therapy in some cancer treatments. The decision, announced today, stems from … Read more